The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade

OncoImmunology

Volumn 4, Issue 7, 2015, Pages 1-4

  Dovedi, S J ^a   Illidge, T M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

IFN; PD 1 adaptive resistance; PD L1; Radiation; Radiotherapy

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1;

ARTICLE; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PROTEIN EXPRESSION; RADIATION DOSE; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84944447485     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1016709     Document Type: Article

References (10)

1. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/ 10.1146/annurev-immunol-032712-100008
2. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174:7516-23; PMID:15944250; http://dx.doi.org/10.4049/jimmunol.174.12.7516
3. Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, Illidge TM. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 2013; 121:251-9; PMID:23086756; http://dx.doi.org/10.1182/blood-2012-05-432393
4. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74; PMID:15776005; http://dx. doi.org/10.1038/nrc1586
5. Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012; 2:153; PMID:23112958; http://dx.doi.org/10.3389/fonc.2012.00153
6. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/ 10.1038/nm0902-1039c
7. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx. doi.org/10.1084/jem.192.7.1027
8. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74:5458-68; PMID:25274032; http://dx.doi.org/10.1158/0008-5472.CAN-14-1258
9. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124:687-95; PMID:24382348; http://dx.doi.org/10.1172/JCI67313
10. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8(+) tumorreactive repertoire infiltrating human tumors. J Clin Invest 2014; 124:2246-59; PMID:24667641; http:// dx.doi.org/10.1172/JCI73639